Berris van Kessel

2.1k citations

33 papers · 1.5k indexed · h-index 14

Hematology top 1%
Oncology top 5%
Molecular Biology
Immunology top 5%
Radiology, Nuclear Medicine and Imaging top 5%

Co-authors: Tuna Mutis Niels W.C.J. van de Donk Henk M. Lokhorst Andries C. Bloem Paul W.H.I. Parren Richard W.J. Groen Inger S. Nijhof Joost M. Bakker
Topics: Multiple Myeloma Research and Treatments (21 papers)Peptidase Inhibition and Analysis (11 papers)Chronic Lymphocytic Leukemia Research (8 papers)
Cited by: Hematology Physiology Oncology
Journals: Journal of Clinical Oncology Blood Clinical Cancer Research
Partner nations: Netherlands United States Denmark

In The Last Decade

Berris van Kessel

30 papers receiving 1.5k citations

Peers

Countries citing papers authored by Berris van Kessel

Since Specialization

Citations

This map shows the geographic impact of Berris van Kessel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Berris van Kessel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Berris van Kessel more than expected).

Fields of papers citing papers by Berris van Kessel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Berris van Kessel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Berris van Kessel. The network helps show where Berris van Kessel may publish in the future.

Co-authorship network of co-authors of Berris van Kessel

This figure shows the co-authorship network connecting the top 25 collaborators of Berris van Kessel. A scholar is included among the top collaborators of Berris van Kessel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Berris van Kessel. Berris van Kessel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab 2020 ·Clinical Cancer Research ·Kristine A. Frerichs,Marloes E.C. Broekmans,(unknown),Berris van Kessel,Martijn W. Heymans,(unknown),Christie P.M. Verkleij,Rengasamy Boominathan,Bhavesh Vaidya,Jocelyn Sendecki,Amy Axel,François Gaudet,Kodandaram Pillarisetti,Sonja Zweegman,Homer Adams,Tuna Mutis,Niels W.C.J. van de Donk	68
2	DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies 2020 ·Blood Cancer Journal ·Simone C. Oostindie,Hilma J. van der Horst,Laurens P. Kil,Kristin Strumane,Marije B. Overdijk,Edward N. van den Brink,(unknown),(unknown),Berris van Kessel,(unknown),Martine E.D. Chamuleau,Tuna Mutis,Margaret A. Lindorfer,Ronald P. Taylor,Janine Schuurman,Paul W.H.I. Parren,Frank J. Beurskens,Esther C.W. Breij	49
3	Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab 2017 ·Clinical Cancer Research ·Jakub Krejcik,(unknown),Inger S. Nijhof,Berris van Kessel,Jeroen F. van Velzen,Andries C. Bloem,Marloes E.C. Broekmans,Sonja Zweegman,Johan van Meerloo,René J.P. Musters,Pino J. Poddighe,Richard W.J. Groen,Christopher Chiu,Torben Plesner,Henk M. Lokhorst,A. Kate Sasser,Tuna Mutis,Niels W.C.J. van de Donk	119
4	CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma 2016 ·Blood ·Inger S. Nijhof,Tineke Casneuf,(unknown),Berris van Kessel,Amy Axel,Khaja Syed,Richard W.J. Groen,Mark van Duin,Pieter Sonneveld,Monique C. Minnema,Sonja Zweegman,Christopher Chiu,Andries C. Bloem,Tuna Mutis,Henk M. Lokhorst,A. Kate Sasser,Niels W.C.J. van de Donk	275
5	Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab 2015 ·Leukemia ·Inger S. Nijhof,Richard W.J. Groen,H M Lokhorst,Berris van Kessel,A C Bloem,(unknown),(unknown),Huipin Yuan,Willy A. Noort,Saskia K. Klein,Anton C. Martens,Parul Doshi,(unknown),Tuna Mutis,Niels W.C.J. van de Donk	203
6	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide 2014 ·Haematologica ·(unknown),Jeroen J. Lammerts van Bueren,Berris van Kessel,Pascale André,Yannis Morel,H M Lokhorst,Niels W.C.J. van de Donk,Paul W.H.I. Parren,Tuna Mutis	89
7	Phase 1/2 Trial Of Lenalidomide In Combination With Cyclophosphamide and Prednisone (REP) In Patients With Lenalidomide-Refractory Multiple Myeloma (REPEAT-study) 2013 ·Blood ·Inger S. Nijhof,Sonja Zweegman,Mark‐David Levin,Harry R. Koene,Aart Beeker,Andries C. Bloem,Gerard M.J. Bos,Laura M. Faber,Saskia K. Klein,(unknown),Ellen van der Spek,Shulamiet Wittebol,Jeroen F. van Velzen,Berris van Kessel,Tuna Mutis,Pieter Sonneveld,Henk M. Lokhorst,Niels W.C.J. van de Donk	1
8	Towards CD38-Targeted Immunochemotherapy of Multiple Myeloma: Significant Improvement of Anti-Myeloma Effects of Lenalidomide, Bortezomib and Dexamethason by CD38-Specific Antibody Daratumumab, Even in Chemotherapy Resistant/Intolerant Patients 2012 ·Blood ·Inger S. Nijhof,Jeroen Lammerts van Bueren,Berris van Kessel,Michel de Weers,Joost M. Bakker,Paul W.H.I. Parren,Henk M. Lokhorst,Tuna Mutis	1
9	The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies 2011 ·Blood Cancer Journal ·Michael S. van der Veer,Michel de Weers,Berris van Kessel,Joost M. Bakker,Shulamiet Wittebol,Paul W.H.I. Parren,H M Lokhorst,Tuna Mutis	81
10	Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients 2011 ·Blood ·Inger S. Nijhof,Michel de Weers,Pascale André,Berris van Kessel,Henk M. Lokhorst,Paul W.H.I. Parren,Yannis Morel,Tuna Mutis	3
11	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab 2010 ·Haematologica ·Michael S. van der Veer,Michel de Weers,Berris van Kessel,Joost M. Bakker,S. Wittebol,Paul W.H.I. Parren,HM Lokhorst,Tuna Mutis	168
12	In Vitro and In Vivo Efficacy of CD38 Directed Therapy with Daratumumab In the Treatment of Multiple Myeloma 2010 ·Blood ·Richard W.J. Groen,(unknown),Frans M.A. Hofhuis,Berris van Kessel,Michel de Weers,Paul W.H.I. Parren,Henk M. Lokhorst,Tuna Mutis,Anton C. Martens	3
13	Improved Myeloma Targeting by Combination of the Human Anti-CD38 Antibody Daratumumab with Lenalidomide and Bortezomib 2010 ·Blood ·Michael S. van der Veer,Michel de Weers,Berris van Kessel,Joost M. Bakker,Shulamiet Wittebol,Paul W.H.I. Parren,Henk M. Lokhorst,Tuna Mutis	2
14	A Unique New Humanized Mouse Model for Multiple Myeloma (MM): Opportunities for Studying MM In Its Natural Environment and for Preclinical Testing 2010 ·Blood ·Richard W.J. Groen,Frans M.A. Hofhuis,(unknown),Berris van Kessel,Michel de Weers,Tuna Mutis,Henk M. Lokhorst,Anton C. Martens	1
15	Solid Pseudopapillary Tumor of the Pancreas: Raising Awareness of a not so Rare Pancreatic Tumor Affecting Young Females 2009 ·European Journal of Pediatric Surgery ·(unknown),Zvi Steiner,Itamar Ashkenazi,Berris van Kessel,(unknown)	4
16	Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma 2008 ·Leukemia Research ·Ellen van der Spek,Andries C. Bloem,Henk M. Lokhorst,Berris van Kessel,(unknown),Niels W.C.J. van de Donk	20
17	Lenalidomide synergizes with simvastatin in myeloma 2007 ·Haematologica ·Ellen van der Spek,A C Bloem,(unknown),Berris van Kessel,(unknown),H M Lokhorst	0
18	Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy 2007 ·Journal of the Neurological Sciences ·M. Eurelings,Henk M. Lokhorst,Nicolette C. Notermans,(unknown),Berris van Kessel,(unknown),Andries C. Bloem,John H. J. Wokke,Martin Poot,Arjan Buijs	2
19	Immunoglobulin gene analysis in polyneuropathy associated with IgM monoclonal gammopathy 2006 ·Journal of Neuroimmunology ·M. Eurelings,Nicolette C. Notermans,Henk M. Lokhorst,Berris van Kessel,Bart C. Jacobs,John H. J. Wokke,Surinder S. Sahota,Andries C. Bloem	2
20	Selective in vitro expansion and efficient retroviral transduction of human CD34⁺ CD38^– haematopoietic stem cells 2002 ·British Journal of Haematology ·(unknown),Andries C. Bloem,Berris van Kessel,Henk M. Lokhorst,Ton Logtenberg,Frank J. T. Staal	12

About Berris van Kessel

Berris van Kessel is a scholar working on Hematology, Genetics and Oncology, having authored 33 papers that have together received 1.5k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (21 papers), Peptidase Inhibition and Analysis (11 papers) and Chronic Lymphocytic Leukemia Research (8 papers). The work is most often cited by research in Hematology (963 citations), Physiology (185 citations) and Oncology (793 citations). Berris van Kessel has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Tuna Mutis, Niels W.C.J. van de Donk, Henk M. Lokhorst, Andries C. Bloem, Paul W.H.I. Parren, Richard W.J. Groen, Inger S. Nijhof, Joost M. Bakker, H M Lokhorst and Michel de Weers. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact